ADA Scientific Sessions Recap—Day #5: Marlon Pragnell, Ph.D.
The ADA’s Scientific Sessions is completed! Here, with the post-day recap, is Marlon Pragnell, Ph.D., head of the complications program…
ADA Scientific Sessions Recap—Day #4: Simi Ahmed, Ph.D.
The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the…
ADA Scientific Sessions Recap—T1D Prevention Research: Jessica Dunne, Ph.D.
There was some really exciting T1D prevention research in day #3, and also screening for type 1 diabetes risk. Here…
ADA Scientific Sessions – The Second Day: Andrew Rakeman, Ph.D.
We’re at the 2019 American Diabetes Association Scientific Sessions, and there’s so much to learn! Here is the recap from…
Sanjoy Dutta, Ph.D.: The Beginning of the ADA Scientific Sessions
The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement…
Breakthrough T1D Heads to ADA’s 79th Scientific Sessions
The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and…
Breakthrough T1D Expresses Profound Loss at the Passing of Helaine Shiff, co-founder of Breakthrough T1D Canada
Breakthrough T1D International is deeply saddened at the loss of one of Breakthrough T1D Canada’s co-founders, Helaine Shiff. “Helaine was…
A Win for the European T1D Community: Zynquista (sotagliflozin) Approved for Type 1 Diabetes
In a second win for the type 1 diabetes (T1D) community, the European Commission has approved Zynquista™ (sotagliflozin) for use…
Breakthrough T1D Names Aaron Kowalski New President and CEO
Chief Mission Officer to assume leadership baton from Derek Rapp After a thorough national search, the Breakthrough T1D International Board…
Breakthrough T1D Nurtures the Young Adult Community by Hosting Networking Conference and Helping Secure Key Internships
More than 120 Young Adults joined Breakthrough T1D for a weekend of networking, learning and connecting at the Breakthrough T1D…
